Global Cell Therapy Market By Use-Type (Research-use and Clinical-use), By Therapy Type (Autologous Therapies and Allogenic Therapies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Cell Therapy Market Overview:

The Cell Therapy Market size is expected to be worth around USD 40.36 billion by 2032 from USD 10.22 billion in 2021, growing at a CAGR of 13.3% during the forecast period from 2022 to 2032.

The cell therapy market report offers a comprehensive analysis request of market segmentation, market dynamics, regional segment analysis, and major key players. Cell therapy is a technology that replaces damaged or dysfunctional cells with healthy functioning cells. Because stem cells can differentiate into the cells needed to repair damaged or defective tissue, they are the main cells used in advanced therapies. In addition, cell therapy can be used to develop regenerative medicines. In addition, by therapy type, the allogenic therapies segment will dominate the market in 2020.

Regenerative medicine is a multidisciplinary area that focuses on maintaining, improving, or restoring cell function, tissue, and cell functions using methods mainly related to cell therapy.

Global Cell Therapy Market Analysis

Use Type Analysis

In 2021, the research-use segment dominated the cell therapy market growth report. It accounted for 62% of the total revenue. Stem cells are mainly used in research projects, leading to a high revenue share of the research-use segment. The region is expected to maintain its dominance between 2023 and 2032.

Cell-based therapies are a great way to repair, restore or regenerate damaged tissue, cells for cells, and organs. These treatments are safe and effective alternatives to conventional methods of treatment. Researchers have made huge investments.

Mesenchymal Stem Cells can address many clinical issues, including modulating the immune response. MSC-based therapy for COVID-19 management has seen a surge in interest from professionals. Coronaviruses need this receptor for entry into the host cells. MSCs injected into host cells have this property and can achieve immunomodulatory effects.

Because of the segment’s low penetration, the clinical-use market’s growth rate is expected to be 13.4%. CARTISTEM, Epicel, and Invossa are all approved cell therapies. However, this is expected to encourage more companies to invest in this segment.

Therapy Type Analysis

The autologous therapies segment held the largest revenue share in the cell therapy market. The segment is expected to continue to dominate during the forecast period. There are many benefits to autologous stem cell therapy transplants, such as ease of availability, no need to identify an HLA-matched recipient, lower risk of serious complications, no risk of GVHD, and no requirement for immunosuppressive therapy. Autologous therapies can also be more affordable than allogenic treatments, which can be attributed to segment growth potential.

Because of the high cost and low relapse rates associated with allogeneic stem cell therapy, the market for the allogenic segment is expected to grow comparatively slowly from 2023-2032. Cell therapy is seeing a boom in cell banking, and companies shifting to allogeneic therapies.

Key Market Segments

By Use-Type

• Research-use
• Clinical-use

By Therapy Type

• Autologous Therapies
• Allogenic Therapies

Market Dynamics

The growing number of clinical studies on cell-based therapies drives the market. This has led to a significant global investment in research and clinical translation. This can be attributed to private and government investment funding agencies offering grants for projects at all stages of clinical trials.

Additionally, regenerative medicine continues to make significant advances and is expected to provide effective treatment options for chronic diseases. Canada is one of the fastest-growing markets, and many companies are trying to take advantage of the huge potential market for cell therapy.

RepliCel invests in multiple projects related to regenerative medicine. The company profile, for example, announced plans in February 2021 to commercialize and conduct clinical trials in Japan for three additional technologies. Two cell-based therapies are available: one for skin renewal and the second for tendon regeneration.

The market has seen a steady increase in the emergence of new technologies that support the development and application of advanced therapies. The main means of exploiting a single product is to create robust candidate portfolios by introducing proprietary cell line technology. Direct cell reprogramming has been gaining significant attention as a new therapeutic approach. This is due to its safety and efficacy.

Fortuna Fix, a private company, is planning to become the first company in the world to start the clinical use of neural stem cell therapy for patients. This will be done by direct reprogramming and can replace any neuronal tissue lost due to neurodegeneration or neurotrauma. This will increase revenue generation.
The cell therapy market has suffered from the COVID-19 virus outbreak.

Despite significant efforts to stop it, there have been some negative impacts. There has been a slowdown in research, with many universities around the globe reducing their enrollments for clinical trials. However, there is still a lot of demand for cell therapy, with companies such as Novartis continuing to grow. MultiStem, a potential treatment for COVID-19, has been recommended by Athersys Inc.

Regional Analysis

North America will hold 55% of the world’s market share in 2021. This large market share can be attributed largely to numerous centers and institutes involved in stem cell therapy R&D. Five of the 8 leading universities worldwide are U.S.-based. These include Institute for Stem Cell Biology and Regenerative Medicine, Yale Stem Cell Center, and Harvard Stem Cell Institute.

Asia Pacific’s field cell therapy industry is expected to grow 14.6% during the forecast period. It is expected that the region’s emerging economies will generate more revenue sources due to the increased investment made by both developers and consumers in advanced medical treatments. Many stem cell alliances in Asia aim to coordinate and focus on R&D. A flexible legal framework has led to patients from Western countries migrating to Asian countries to seek treatment.

Key Regions and Countries covered іn thе rероrt:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Market Share & Key Players Analysis:

U.S. FDA approvals have been granted to numerous companies for stem-cell therapy for different diseases and infections. Stemedica Cell Technologies, Inc. was granted Investigational New Drug Approval by FDA to conduct phase II trials on intravenously administered allogeneic MSCs for covid-20 patients. They are attractive as a novel treatment for COVID-19 due to their immunomodulatory and immunogenicity.

Advanced cell therapy manufacturing includes some major key market players: PHARMICELL Co. Ltd, Anterogen co., ltd., Osiris Therapeutics Inc. medipost co., ltd., smith & nephew, tameika cell technologies, inc., Osiris therapeutics, inc, Danaher corporation, pharmicell co., ltd.

Маrkеt Кеу Рlауеrѕ:

• Kolon TissueGene Inc.
• PHARMICELL Co. Ltd
• Anterogen co., ltd.
• Osiris Therapeutics Inc.
• JCR Pharmaceuticals Co. Ltd.
• Vericel Corporation
• Castle Creek Biosciences Inc.
• Celgene Corporation
• Danaher corporation
• NuVasive, inc.
• smith & nephew
• Osiris therapeutics, inc
• tameika cell technologies, inc.
• Other major Players

For the Cell Therapy Market research study, the following years have been considered to estimate the market size: